公开(公告)号：US5847112A

公开(公告)日：1998-12-08

申请号：US970460

申请日：1997-11-14

申请人： Peter J. Kniskern ,  William J. Miller ,  Arpi Hagopian ,  Charlotte C. Ip ,  John P. Hennessey, Jr. ,  Dennis J. Kubek ,  Pamela D. Burke

发明人： Peter J. Kniskern ,  William J. Miller ,  Arpi Hagopian ,  Charlotte C. Ip ,  John P. Hennessey, Jr. ,  Dennis J. Kubek ,  Pamela D. Burke

IPC分类号： A61K39/00 ,  A61K39/09 ,  A61P31/04 ,  C07H1/08 ,  C08B37/00 ,  C12N1/20 ,  C12P19/00 ,  C12P19/04 ,  C12R1/46

CPC分类号： A61K39/092 ,  C12P19/04

摘要： Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1.0 and 1.4, intrinsic viscosities between 0.6 and 3.0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.

摘要翻译： 来自肺炎链球菌的特异性荚膜多糖制剂，其平均每分子平均小于约1000个寡糖重复单位，多分散性在1.0至1.4之间，特性粘度在0.6至3.0dL / g之间，小于3％的特异性多糖污染 通过组特异性C-多糖通过新方法产生。 新型特异性多糖产物可用于制备疫苗，特别是包含与T细胞刺激性载体蛋白连接的新型多糖的共价缀合物。 包含新型多糖的疫苗可用于预防感染和与肺炎链球菌感染相关的疾病。

公开(公告)号：US5623057A

公开(公告)日：1997-04-22

申请号：US246394

申请日：1994-05-20

申请人： Stephen Marburg ,  Richard L. Tolman ,  Peter J. Kniskern ,  William J. Miller ,  Arpi Hagopian ,  Charlotte C. Ip ,  John P. Hennessey, Jr. ,  Dennis J. Kubek ,  Pamela D. Burke

发明人： Stephen Marburg ,  Richard L. Tolman ,  Peter J. Kniskern ,  William J. Miller ,  Arpi Hagopian ,  Charlotte C. Ip ,  John P. Hennessey, Jr. ,  Dennis J. Kubek ,  Pamela D. Burke

IPC分类号： A61K39/00 ,  A61K38/16 ,  A61K39/02 ,  A61K39/09 ,  A61K39/095 ,  A61K39/295 ,  A61K39/395 ,  A61K47/36 ,  A61P29/00 ,  C07K20060101 ,  C07K1/113 ,  C07K1/14 ,  C07K14/00 ,  C07K14/195 ,  C07K14/22 ,  C07K14/315 ,  C07K14/41 ,  C07K17/02 ,  C07K17/10 ,  C08B37/00 ,  C12P19/04 ,  C12P21/00 ,  C12R1/36 ,  C12R1/46 ,  A61K39/385

CPC分类号： A61K39/095 ,  A61K39/092 ,  A61K2039/6068 ,  A61K2039/627

摘要： A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.

摘要翻译： 通过新方法生产包含与免疫原性载体蛋白连接的来自肺炎链球菌（Streptococcus pneumoniae）（肺炎球菌，Pn））的部分水解，高度纯化的荚膜多糖（Ps）的新型缀合疫苗。 该缀合物可用于预防肺炎球菌感染。 包含1至10种不同的肺炎球菌多糖 - 免疫原性蛋白（Pn-Ps-PRO）缀合物的混合物的疫苗诱导针对多糖成分衍生的同源病原体的广泛保护性受体免疫应答。 年龄小于2岁的幼儿和婴儿通常无法对Pn-Ps单独施加保护性免疫应答，在用这些Pn-Ps-PRO缀合物接种疫苗后，会显示出保护性的免疫应答。

公开(公告)号：US10653757B2

公开(公告)日：2020-05-19

申请号：US14234269

申请日：2012-07-20

申请人： Michael R. Yeaman ,  John E. Edwards, Jr. ,  Scott G. Filler ,  Ashraf S. Ibrahim ,  Yue Fu ,  John P. Hennessey, Jr.

发明人： Michael R. Yeaman ,  John E. Edwards, Jr. ,  Scott G. Filler ,  Ashraf S. Ibrahim ,  Yue Fu ,  John P. Hennessey, Jr.

IPC分类号： A61K39/00 ,  A61K39/09 ,  A61K39/085 ,  A01N63/04 ,  A61K36/06 ,  A61K45/06

摘要： The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.

公开(公告)号：US20150273031A1

公开(公告)日：2015-10-01

申请号：US14234269

申请日：2012-07-20

申请人： Michael R. Yeaman ,  John E. Edwards, JR. ,  Scott G. Filler ,  Ashraf S. Ibrahim ,  Yue Fu ,  John P. Hennessey, JR.

发明人： Michael R. Yeaman ,  John E. Edwards, JR. ,  Scott G. Filler ,  Ashraf S. Ibrahim ,  Yue Fu ,  John P. Hennessey, JR.

IPC分类号： A61K39/00 ,  A61K45/06

CPC分类号： A61K39/0002 ,  A61K45/06 ,  A61K2039/55505 ,  A61K2039/58

摘要： The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.

摘要翻译： 本发明的特征在于一种针对金黄色葡萄球菌接种哺乳动物的方法，其包括以下步骤：a）鉴定处于发生金黄色葡萄球菌皮肤或软组织感染风险的哺乳动物; 和b）向所述哺乳动物施用免疫原性量的疫苗，其包含在药学上可接受的培养基中包含分离的凝集素样序列（Als）3蛋白（Als3p）或其免疫原性片段的多肽。